The course of the study and clinical trial
In the clinical trial, diabetic experts tested Ascarx in 119 type 2 diabetic patients. The aim was to test the effectiveness of the compound in balancing blood glucose, reducing hemoglobin A1c and blood lipids (cholesterol and triglycerides).
103patients with type-2 diabetes completed a 12-week treatment and follow-up.
- Blood glucose values decreased from 211 mg to 133 mg (37%).
- Hemoglobin A1c decreased from 9.0% to 7.1% (22%).
- Average cholesterol dropped to 185 mg (13%).
- Triglycerides dropped to 160 mg (40%).
Of 13 patients treated with insulin at the beginning of the study, 5 discontinued insulin and were treated with tablets only and 8 reduced their insulin requirements by 30%.
In the clinical findings, Ascarx benefits were astonishing. Specifically, two patients who had recently been treated with retinal photocoagulation were completely healed and in another 6 patients the retinal injury stopped progressing. Also, in 3 patients with significant renal impairment, there was a marked improvement in renal function. Finally, 5 men with impotence improved their sexual activity.
Only 12 patients did not respond to the treatment with Ascarx.
Patients’ documentation from the clinical trial
Case studies from a group of patients, who participated in the clinical trial
Participants’ names are confidential in accordance to paragraph 1.6 of the Ministry of Health Procedure for Human Medical Experiments
To view the data, press the +
M, 54 years old at trial
Type 2 diabetes for 23 years (started as gestational diabetes), with complications of retinal inflammation, vitrectomy, diabetic neuropathy and peripheral vascular disease.
The patient was treated with insulin for the previous ten years before the trial and also diagnosed with rheumatoid arthritis. At the same time, she started taking steroids and Ascarx.
During the treatment, it was decided to continue with the insulin in addition to the Ascarx. Thereafter, according to the blood glucose values, the dose of insulin was reduced and upon discontinuation the patient began taking metformin and glibenclamide . Blood glucose levels dropped to 130 mg and HbA1C decreased from 10.6% to 6.3%. The patient did not suffer from any side effects while taking Ascarx.
Months after the trial, she reported that she stopped taking glibenclamide, felt good and the sugar values were maintained within normal limits.
M, 54 years old at trial
Suffered from diabetes since 2004. Because of obesity and high sugar levels the patient was hospitalized for urgent care: glucose level 514 mg and raised lipids (cholesterol 706 mg, triglycerides 1520 mg). The HbA1c was 15.1%. In the hospital he started taking insulin as well as Glipizide, Gluco-Rite and Metformin.
A week later, when he returned home, he began receiving treatment with Ascarx, and for the first two weeks we were able to reduce the use of Glipizide by half and even reduce the dose of Metformin. Blood sugars dropped to normal within 3 months of treatment, cholesterol dropped to 219 mg, triglycerides to 177 mg, and HbA1c to 6.7%. He feels good and continues the treatment with Ascarx without any side effects reported.
S, 54 years old at trial
He was diagnosed with type 2 diabetes in 1999. Also suffered from high blood pressure and high blood lipid levels. Despite drug treatment with Metformin and Glyburide combined with exercise and weight loss, his sugar levels still ranged between 200 and 250mg and the HbA1c was 9.8%. Blood lipids were still high. He began treatment with Ascarx and within four weeks he was able to stop the other medication. Blood glucose after fasting was 100mg +/-10mg. After the study he reported feeling healthy and that he maintains physical activity and correct diet.
A, 56 years old at trial
The patient joined the trial after suffering from type 2 diabetes for the previous six years. In addition, he had high blood pressure, gout and high blood lipid levels. His blood sugar was particularly high averaging 350mg and a high HbA1c at 10.7%. Cholesterol and triglycerides were also significantly high. He took Glyburide and Prandase (acarbose ) and statins for blood lipid treatment.
A, 70 years old at trial
The patient joined the trial after suffering from type 2 diabetes for 30 years, taking Gluben (glibenclamide) , Glucophage, and Prandase . He developed retinal inflammation following diabetes (diabetic retinopathy), and therefore he had to undergo retinal laser therapy (photocoagulation). Weeks before the trial he switched to insulin therapy because of high sugar levels.
He started high-dose treatment with Ascarx (2 tablets, three times a day) and after 16 weeks,was able to stop using Glucophage and Prandase. The fasting glucose began to stabilize, but the most surprising result was that during the course of treatment with Ascarx, his ophthalmologist reported that retinal inflammation had completely disappeared (NO DIABETIC RETINOPATHY). In the follow up examination we conducted, the HbA1c was stabilized at 7.2% and he continued to work and remain active.
C,75 years old at trial
Diabetic for 20 years and receiving insulin therapy during the 8 years preceeding the trial. He had atherosclerotic heart disease and heart failure, peripheral vascular disease, high blood pressure, and kidney failure. Initial blood glucose tests, following fasting, ranged from 150mg to 250 mg. His cholesterol was high with advanced kidney failure.He started treatment with Ascarx and after three months of treatment he was able to stop the injection of insulin and started oral drug therapy with Glucophage. His sugar levels following fasting were 130mg +/-20mg. During this time, the HbA1c level dropped from 11.1% to 7.2%.Notably, renal failure has resolved and creatinine index has returned to normal. After two years of treatment with Ascarx, the patient doesn’t have insulin treatment and controls diabetes with no side effects.
J, 58 years old at trial
The patient had an 8 year history of type 2 diabetes. He suffered from symptoms such as hyperglycemia and nocturnal urination, accompanied by fatigue, two years before being diagnosed with diabetes. When he was first diagnosed, he was recommended to lose weight and change his lifestyle. He had trouble losing weight and started taking Glibenclamide 2.5 mg every morning, but stopped after feeling dizzy with excessive sweating, nausea and nervousness. At the first treatment session, the HbA1c was 8.0%, glucose 160mg +/-20 mg, total cholesterol of 260 mg, LDL cholesterol 148 mg, HDL cholesterol 36mg and triglycerides 250 mg. His blood pressure, measured several times over a year, was consistently above average at 140/90mmHg.
He started taking two Ascarx tablets twice a day. For the first two weeks, he complained of abdominal pain, flatulence, and frequent bowel movement. However his sugar level was lower, he was feeling more energetic, without nocturnal urination and he had resumed sexual function, which encouraged him to continue the treatment. The HbA1c level was 6.6% after three months (17% reduction), total cholesterol was 210 mg, LDL cholesterol 140 mg, HDL cholesterol 42 mg and triglycerides 158 mg.
Q, 69 years old at trial
The patient was sent to the hospital for mild chest pain, with diabetes, cholesterol around 270 mg (LDL 170 mg) and triglycerides around 600 mg.His sugar level was 170 mg, HbA1C , 7.8% cholesterol 570 mg, triglycerides 295 mg (normal value up to 150) and he underwent cardiac catheterization. No myocardial injury was found.
The doctors recommended insulin treatment with Lantus 30 units.
He started treatment with Ascarx, getting two tablets three times a day. Within three weeks, sugar levels dropped below 100 mg and triglyceride levels dropped to 158 mg. Cholesterol dropped to 180 mg and the LDL cholesterol to 120 mg. The HbA1C level dropped to 6.4%.
Summary of the study and the clinical trial
Ascarx is a combination containing a herbal mixture whose active ingredients have also been studied by research groups around the world and demonstrated their ability to lower blood glucose levels.
The study was conducted in Israel by Dr. Dov Fogel and his team in collaboration with ” Maccabi Health Services ” for type-2 diabetic patients according to a protocol approved by the various committees responsible for human experimentation (Helsinki Commission, and trial registration ISRCTN 12562776).
It was found that patients who received Ascarx treatment, had an average 37% drop on their blood glucose level.
The compound was highly effective in patients whose blood glucose levels were particularly high at the start of treatment.
There was also a significant decrease in triglycerides (24%) and total cholesterol (13%).
Dr. Fogel noted about the results of the experiment: “We are very excited about the effects we have seen, and we are eager to bring this plant extract to patients.”
Dr. Fogel and his team are currently investigating the impact of Ascarx and its natural components on organ recovery from damage in diabetes, such as kidney, eyes, blood vessels and more.